Application of Nanoparticles for Immunotherapy of Allergic Rhinitis
Kaiqiang Li,Jing Jin,Yimin Yang,Xuling Luo,Yaling Wang,Aibo Xu,Ke Hao,Zhen Wang
DOI: https://doi.org/10.2147/ijn.s484327
IF: 7.033
2024-11-27
International Journal of Nanomedicine
Abstract:Kaiqiang Li, 1, 2, &ast Jing Jin, 3, &ast Yimin Yang, 4, &ast Xuling Luo, 4 Yaling Wang, 1 Aibo Xu, 1 Ke Hao, 1, 2 Zhen Wang 1, 2 1 Laboratory Medicine Center, Allergy Center, Department of Transfusion Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People's Republic of China; 2 Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Hangzhou, Zhejiang, 310063, People's Republic of China; 3 Laboratory Medicine Center, Zhejiang Center for Clinical Laboratories, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People's Republic of China; 4 College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, Zhejiang, 310014, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ke Hao; Zhen Wang, Email ; Allergen Immunotherapy (AIT) is the only etiological therapeutic method available for allergic rhinitis (AR). Currently, several options for AIT in the market, such as subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), have different routes of administration. These traditional methods have achieved encouraging outcomes in clinic. However, the side effects associated with these methods have raised the need for innovative approaches for AIT that improve safety, shorten the course of treatment and increase local drug concentration. Nanoparticles (NPs) are particles ranging in size from 1 to 100 nm, which have been hired as potential adjuvants for AIT. NPs can be employed as agents for modulating immune responses in AR or/and carriers for loading proteins, peptides or DNA molecules. This review focuses on different kinds of nanoparticle delivery systems, including chitosan nanoparticles, exosomes, metal nanoparticles, and viral nanoparticles. We summarized the advantages and limitations of NPs for the treatment of allergic rhinitis. Overall, NPs are expected to be a therapeutic option for AR, which requires more in-depth studies and long-term therapeutic validation. Keywords: allergen immunotherapy, nanoparticles, allergic disease, subcutaneous immunotherapy Graphical Allergic rhinitis (AR) is an increasingly serious respiratory disease affecting about 600 million populations worldwide. 1 Common symptoms of AR include rhinorrhea, nasal itching, pruritus and sneezing. 2 These symptoms are not fatal, but the quality of the patients' lives is seriously impaired with altered sleep quality, fluctuating emotion and poor daily performance in school or office. 3,4 Effective treatments can greatly improve the life quality of those patients with AR. As an allergic disease, the special immune responses caused by allergens contribute to the progress of AR. A variety of immune cells participate in these reactions including nasal epithelial cells, mast cells, eosinophils, basophils, T helper 2 cells (Th2 cells), group 2 innate lymphoid cells (ILC2s), antigen-presenting cells and B cells. 5–7 Allergen immunotherapy (AIT) is the only etiological therapy for AR, which aims to reshape the immune system by repeatedly administrating pathogenic allergens to patients in a controlled manner. 8 The mechanisms of AIT mainly include inducing a rapid decline in the degranulation of basophils and mast cells, triggering the transformation from Th2-type to Th1-type reaction, and resulting in the transformation of allergen-specific IgE to IgG4. AIT can induce immune tolerance, thus attenuating or even eliminating allergic reactions and subsequent immune events in patients who suffer from AR. 9–13 At present, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most common AIT treatments, exhibiting excellent outcomes. However, long-term side effects and substandard local drug concentrations have raised the requirement for innovative approaches for AIT to address these pitfalls. Currently, the application of nanoparticles (NPs) in the treatment of AR has been put forward and validated. NPs are particles of matter ranging from 1 to 100 nm in size, making them easily absorbed by cells. 14 NPs can be employed as agents for modulating immune responses or/and carriers for loading allergens and protecting them from degradation. 15–17 At present, there are various types of NPs available for use in AIT. According to whether they can be degraded in vivo, these particles are classified into biodegradable and non-biodegradable NPs. Biodegradable NPs mainly include n -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology